MKI67 and neoplasm: Various combinations of markers have been assessed to develop a robust IHC panel for routine pathology reporting, most recently adding Ki67 to ER, PR, HER2 to better assess proliferative luminal tumours (Cheang et al, 2009; Hugh et al, 2009).